Mens Health · Supplementary · from Mens Health

Case 2: Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms

Patient Presentation

Demographics: 64-year-old male retired teacher

Chief Complaint: "I'm up four or five times a night to urinate and I can barely make it to the bathroom during the day."

History of Present Illness: The patient presents with progressive lower urinary tract symptoms (LUTS) that have worsened significantly over the past 18 months. He reports both storage and voiding symptoms. Storage symptoms include nocturia 4-5 times per night (severely disrupting sleep), urinary urgency with occasional urge incontinence (2-3 episodes per week requiring a pad), and frequency of urination every 1-1.5 hours during the day.

Voiding symptoms include hesitancy, a weak and intermittent stream, straining to initiate urination, terminal dribbling, and a sensation of incomplete emptying. He reports that it takes him 2-3 minutes to complete voiding, compared to under a minute previously. He has developed anxiety about long car rides and avoids situations where bathrooms are not immediately accessible.

He denies gross hematuria, dysuria, or perineal pain. He has no history of urinary retention, urinary tract infections, or kidney stones. He tried over-the-counter saw palmetto for 6 months without noticeable improvement.

Past Medical History:

• Hypertension (well-controlled)
• Hyperlipidemia
• Osteoarthritis of both knees
• No prior urological history

Medications:

• Lisinopril 10 mg daily
• Rosuvastatin 10 mg daily
• Acetaminophen 500 mg PRN for knee pain
• Saw palmetto 320 mg daily

Social History:

• Non-smoker, social alcohol (1-2 glasses of wine on weekends)
• Retired, active in community volunteering
• Married, sexually active
• Drinks 3-4 cups of coffee daily, 2 cups of tea in the evening
• Adequate fluid intake (~2.5 L/day)

Family History:

• Father: BPH requiring TURP at age 70
• Brother: Prostate cancer diagnosed at 68
• Mother: Hypertension

Physical Examination

• Vital Signs: BP 128/76 mmHg, HR 68 bpm, RR 14, Temp 36.7°C, SpO2 98% RA, BMI 26.8
• General: Well-appearing male in no distress
• Abdomen: Soft, non-tender, no suprapubic fullness or mass, no costovertebral angle tenderness
• Genitourinary: Normal external genitalia, no meatal stenosis, no urethral discharge
• Digital Rectal Examination: Prostate symmetrically enlarged (estimated 60-70 g), smooth surface, firm-rubbery consistency, no nodules or induration, median sulcus obliterated, non-tender, normal rectal tone
• Neurological: Normal perineal sensation, intact bulbocavernosus reflex, normal lower extremity strength and reflexes

Workup and Results

Laboratory Studies:

Imaging/Additional Studies:

• IPSS (International Prostate Symptom Score): 24/35 (severe)
• IPSS Quality of Life score: 5/6 (mostly dissatisfied)
• Uroflowmetry: Qmax 8.2 mL/s (normal > 15 mL/s), voided volume 180 mL, flow pattern plateau-shaped
• Post-void residual (PVR): 145 mL (normal < 50 mL, clinically significant > 100 mL)
• Transrectal ultrasound: Prostate volume 68 mL, prominent median lobe protruding into the bladder base, no suspicious lesions
• Renal ultrasound: No hydronephrosis, normal kidney size bilaterally, mild bladder wall thickening (trabeculation)
• Frequency-volume chart (3-day): Average daytime frequency 12, nocturia 4.5, nocturnal polyuria index 38% (normal < 33%), 24-hour urine volume 2.8 L

Clinical Image

Anatomical illustration showing the zonal anatomy of the prostate gland with transition zone hyperplasia in BPH, bladder outlet obstruction mechanics, median lobe enlargement, and resulting detrusor muscle changes including trabeculation and diverticula formation. Source: Educational illustration.

Diagnosis

Benign Prostatic Hyperplasia (BPH) with Moderate-to-Severe Lower Urinary Tract Symptoms (LUTS), Bladder Outlet Obstruction, and Nocturnal Polyuria

Key Diagnostic Criteria:

• IPSS 24/35 (severe symptoms) with significant quality of life impact
• Prostate volume 68 mL with prominent median lobe on TRUS
• Uroflowmetry Qmax 8.2 mL/s confirming obstructive flow pattern
• Elevated PVR of 145 mL indicating incomplete emptying
• Bladder wall trabeculation on ultrasound suggesting detrusor compensation/decompensation
• Nocturnal polyuria index 38% contributing to nocturia
• PSA 3.8 ng/mL with free PSA 28% consistent with benign enlargement (PSA density 0.056 ng/mL/cc)

Treatment Plan

1. Combination pharmacotherapy (prostate > 40 mL with severe LUTS):

• Alpha-1 adrenergic blocker: tamsulosin 0.4 mg daily (relaxes prostatic smooth muscle for rapid symptom relief within 1-2 weeks)
• 5-alpha reductase inhibitor: dutasteride 0.5 mg daily (reduces prostate volume by 20-25% over 6-12 months, reduces risk of acute urinary retention and need for surgery)
• Combination therapy shown in CombAT trial to be superior to either agent alone for prostates > 40 mL

1. Nocturia management:

• Fluid restriction after 6 PM, eliminate evening caffeine (tea)
• Timed diuretic therapy: furosemide 20 mg in early afternoon to shift fluid mobilization to daytime hours
• Leg elevation for 30 minutes in late afternoon to reduce peripheral edema redistribution
• If nocturia persists, consider desmopressin 25 mcg intranasal at bedtime (with sodium monitoring)

1. Behavioral modifications:

• Bladder training with scheduled voiding every 2 hours, gradually increasing intervals
• Double voiding technique to reduce PVR
• Reduce caffeine to 1-2 cups before noon only
• Pelvic floor muscle exercises (male Kegel program)

1. Discontinue saw palmetto (insufficient evidence for prostate > 40 mL)
2. Counseling on 5-ARI side effects: Discuss potential sexual side effects (decreased libido 2-4%, erectile dysfunction 5-7%, ejaculatory dysfunction 1-2%), inform that PSA will decrease by approximately 50% (double PSA value for cancer screening interpretation)
3. Follow-up: IPSS, uroflowmetry, and PVR at 6 weeks (alpha-blocker response), 3 months, 6 months, then annually; PSA at 6 months (new baseline); consider urological referral for minimally invasive therapy (Rezum, UroLift, or Aquablation) if inadequate response at 6 months or patient preference

Key Learning Points

• Combination therapy with an alpha-blocker plus a 5-alpha reductase inhibitor is the evidence-based standard for men with prostates > 40 mL and moderate-to-severe LUTS, reducing risk of symptom progression, acute retention, and surgical intervention
• Nocturia in older men is often multifactorial: BPH-related storage dysfunction, nocturnal polyuria (from peripheral edema redistribution, reduced nocturnal ADH), and sleep disorders all contribute and should be independently assessed with a frequency-volume chart
• Free PSA percentage helps distinguish benign from malignant causes of PSA elevation; values > 25% strongly favor BPH, while values < 10% raise concern for prostate cancer
• Post-void residual > 100 mL indicates clinically significant incomplete emptying and is a risk factor for urinary retention, UTI, and upper tract damage; serial monitoring is essential
• Median lobe enlargement causes obstructive symptoms disproportionate to overall prostate size and may respond less well to medical therapy, making it an important factor when considering surgical options

All cases for this lecture as Markdown